19 / 26
Journal of Transmitted Diseases and Immunity
ISSN: 2573-0320
Page 78
Volume 4
May 10-11, 2018
Frankfurt, Germany
Immunology Research 2018
Tissue Science 2018
JOINT EVENT
2 2
n d
E d i t i o n o f I n t e r n a t i o n a l C o n f e r e n c e o n
Immunology and
Evolution of Infectious Diseases
&
1 2
t h
E d i t i o n o f I n t e r n a t i o n a l C o n f e r e n c e o n
Tissue Engineering and
Regenerative Medicine
Background:
Treatment of cutaneous lesions by radiotherapy
or surgery entails destruction or excision of normal tissue
surrounding a lesion. Lesions may be extensive, at sites of poor
healing, or adjacent to difficult to reconstruct tissues. This may
make treatment by these modalities impossible, or may result in
poor cosmetic or functional outcomes. Photodynamic therapy
(PDT) offers an important alternative. PDT is a highly selective
treatment which can achieve total eradication of malignant and
premalignant lesions with minimal damage to normal tissues.
Methods & Results:
Patient one had an extensive port wine
stain. This had been treated by radioactive Thorium in the past,
but this had caused multiple basal cell carcinomas to develop
over the whole area. Patient two had a substantial basal cell
carcinoma on the back. Photofrin was employed and additional
light irradiation using a laser fibre inserted into the base of a thick
lesion. Patient three has Gorlin syndrome and had developed a
basal cell carcinoma on the lower eye lid. This was eradicated
by Photofrin PDT. Patient four presented with an extensive thick
plaque of Bowen’s disease covering his knee. This resolved after
several treatments of Metvix PDT. Patient five was referred with
an extensive area of extra-mammary Paget’s disease. This was
eradicated by Photofrin PDT.
Conclusion:
PDT is no longer simply a treatment option for
superficial cutaneous non-melanoma carcinoma and pre-
malignant conditions. It is the preferred treatment in a range of
challenging situations where surgery and radiotherapy are likely
to produce suboptimal results.
ernest.allan@christie.nhs.ukPDT - treating the untreatable
E Allan
1
, D Allan
2, 3
and
Laura Foster
1
1
Christie NHS Foundation Trust, UK
2
Salford Royal NHS Foundation Trust, UK
3
University of Manchester-Manchester Academic Health Science Centre, UK
J Transm Dis Immun 2018, Volume 2
DOI: 10.21767/2471-8084-C1-003